Category
THROMBOPOIETIN RECEPTOR AGONIST
THROMBOPOIETIN RECEPTOR AGONIST
Consistent
Purity
Global-Ready
Molecules
Advanced
Manufacturing
Scalable
Production
Partnership
Support
Eltrombopag Olamine API has been developed by ASANA Pharmaceutical as part of its hematology-focused product portfolio. Eltrombopag Olamine API, registered under CAS number 496775-62-3, functions as a thrombopoietin receptor agonist used in the treatment of chronic immune thrombocytopenia and related platelet disorders.
ASANA Pharmaceutical is dedicated to the development and manufacturing of advanced APIs in the hematology segment, including Eltrombopag Olamine. Known for its role in platelet production support, this thrombopoietin receptor agonist is produced under stringent quality systems aligned with global regulatory frameworks. ASANA serves clients across North America, Europe, and Asia through a well-established network and best-in-class manufacturing capabilities.
ASANA Pharmaceutical partners closely with research labs, regulatory consultants, and clinical suppliers to bring forward safe and effective treatments for blood-related disorders. Eltrombopag Olamine [CAS No. 496775-62-3] is a critical component in the management of chronic immune thrombocytopenia, helping stimulate platelet production in patients with low counts. As global demand for hematologic therapies increases, ASANA is focused on delivering:
Eltrombopag Olamine API are available on public databases such as Wikipidia!